Top 50 Biotech VC Funds in Germany
A list of 50 VC funds that invest in Biotech startups based in Germany. We rank investors based on the number of investments they made in Biotech companies from Germany. We update this investor list every month.Top 50 Biotech VC Funds in Germany
The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise,entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.
Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.
Show more
Investment focus
- Software, Information Technology, Biotechnology
- Seed, Series A, Funding Round
- Germany, Switzerland, United States
Portfolio highlights
- Graswald — Graswald engages in the creation of natural and digital 3D worlds for the entertainment industry.
- CustomSurg — RETHINKING TRAUMA SURGERY At CustomSurg we are changing the treatment of complex bone fractures from a subjective to an objective approach, through personalized solutions.
- Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Seed
- United States, Germany, Belgium
Portfolio highlights
- Actym Therapeutics, Inc. — Actym Therapeutics is developing key biotech to help target intractable immune pathways in the tumor microenvironment.
- smartbax — We develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
- Glox Therapeutics — Developing novel precision antibiotics based on protein bacteriocins, to target Gram-negative Antimicrobial Resistant (AMR) pathogens.
Zusammen gestalten wir die Unternehmen von morgen.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series A, Funding Round, Series B
- Germany, Austria, Canada
Portfolio highlights
- AMSilk — AMSilk produces and distributes high-quality silk biopolymers for use in textile products, medical devices, and cosmetics.
- HawkCell — A plug-and-play solution turning human MRI into the first animal-dedicated imaging enhanced with AI algorithms. A unique MRI solution.
- Look Up Space — Lookup space is the next global leader for space safety, security and sustainability
NRW.BANK is the development bank for the state of North Rhine-Westphalia. It supports its owner – the state of North Rhine-Westphalia – in fulfilling its tasks, notably in the fields of structural, economic, social and housing policy. NRW.BANK pools the promotion and development programmes of the state of North Rhine-Westphalia, the FederalRepublic of Germany and the European Union and combines them with its own equity and debt products and advisory services. It offers the full range of financial products in three areas “Economy”, “Housing”, and “Infrastructure/Municipalities”. NRW.BANK operates in a competitively neutral manner as a partner of banks and savings banks.
Show more
Investment focus
- Biotechnology, Software, Information Technology
- Seed, Series A, Series B
- Germany, United States
Portfolio highlights
- widu — widu enables real estate and accommodation companies to source visuals (photography, video, drone) at scale through its serviced marketplace
- bNear — bNear is the digital space for all distributed- & hybrid teams - Safe and convenient in Microsoft Teams!
- Companyon Analytics — Companyon Analytics provides data security, cloud infrastructure, information technology, technical solutions, and consultancy services.
KfW gives impetus to economic, social and ecological development worldwide. As a promotional bank under the ownership of the Federal Republic and the Länder (federal states), it offers support to encourage sustainable improvement in economic, social, ecological living and business conditions, among others in the areas of small and medium-sizedenterprise, entrepreneurialship, environmental protection, housing, infrastructure, education finance, project and export finance, and development cooperation.
Show more
Investment focus
- Biotechnology, Software, Health Care
- Funding Round, Series A, Series B
- Germany, India, Kenya
Portfolio highlights
- Uniper — Uniper is an international energy company with about 11,000 employees. They combine a balanced portfolio of technologically advanced large-scale assets with outstanding technical and commercial expertise. Uniper is a German energy company based in Dusseldorf, North Rhine-Westphalia. It was formed by the separation of E.ON's fossil fuel assetsinto a separate company that began operating on 1 January 2016.
- Vectoflow — Vectoflow is an innovative company developing fluid-dynamic metrology devices for fluid flow and dynamics measurement. It offers standardized and customized flow measurement technology that measures the static and total pressure, velocity, and angle of attack of a flow. These products are used in motorsport, aviation, turbine machine development,and research sectors.
- Electrochaea — Electrochaea is commercializing a disruptive, scalable technology to convert electric power into methane, the principal component of natural gas. Using CO2 as a feedstock gas, power can be efficiently converted to renewable natural gas for power storage, for transportation fuels, or for transmission via a natural gas network. The company licensedtechnology from the University of Chicago and is led by the Nidus Partners, a St. Louis investment group specializing in renewable energy. Mich Hein, a Nidus Managing Partner, serves as CEO.Electrochaea has developed a commercially viable and disruptive solution for utility-scale energy storage, grid balancing, and carbon reuse. Their proprietary process converts low-cost and stranded electricity and carbon dioxide into pipeline-grade renewable gas for direct injection into the existing natural gas grid, a conversion process known as “power-to-gas”.
Bayern Kapital (founded at the end of 1995) is a wholly owned subsidiary of the LfA Foerderbank Bayern (Bavaria‘s development bank). Bayern Kapital’s objective is to finance research and development as well as the market launch of new products, product diversifications, and expansion of the market share.The requesting company has to be located inBavaria. Industries are e. g. IT/software, life sciences, new materials, micro-systems and environmental technologies.Bayern Kapital and its funds have invested in more than 250 companies and currently manages funds to the value of EUR 340 m. The five investing funds currently managed by Bayern Kapital are Seedfonds Bayern, Clusterfonds Start-Up!, Innovationsfonds, Innovationsfonds EFRE and Wachstumsfonds Bayern.
Show more
Investment focus
- Software, Health Care, Information Technology
- Seed, Series A, Funding Round
- Germany, United States, Finland
Portfolio highlights
- VITAS — Our system is based on Deep Learning and offers an intelligent voice assistant for customer service. Use cases can be found in both the SME and enterprise market for all companies with many standardized customer calls. VITAS answers the telephone, checks data in real time, can react flexibly to requests and offers the caller a self-service withoutwaiting time. Areas of application include restaurants, workshops, medical practices, taxi centres, insurance companies, banks and tax consultants.
- BOX ID Systems — BOX ID Systems develops and offers an end-to-end location & process mining solution to cost effectively track millions of logistics assets digitally throughout the industrial supply chain across Europe and the World - including site-to-site, on-premises and indoor buildings digital twin of supply chain processes. The system is built on aspecialized analytics software platform, sensorik tracking devices and efficient data-, device- and user-management tools, including functions to support process automation and optimization. Industrial and automotive production customers benefit from making their logistics processes more efficient and cost optimized, with 100% transparency within their critical processes throughout the entire supply chain.
- Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
TGFS - Technologiegruenderfonds Sachsen is an early stage VC fund targeting high tech startups with strong growth potential. The fund invests into ventures located in Saxony/Germany, Europe's leading semiconductor cluster. The team has invested into more than 120 companies so far, including more than 40 investments from the currentfund.
Show more
Investment focus
- Software, Information Technology, Manufacturing
- Seed, Funding Round, Series A
- Germany, United States
Portfolio highlights
- MiViA — From microstructure segmentation to grain size measurement! Our AI engine provides a fast and reliable metallographic analysis for metallic products.}
- watttron — Watttron invents a revolutionary heating system that can heat up surfaces heterogeneously.Watttron develops an innovative heating technology that can be used in various industrial processes. It is superior to current heating systems in many ways and offers a number of advantages. On the following pages, you will find information about possibleapplications and opportunities.The company is located in the Technologie- und Gründerzentrum Freital – a technology and start-up center on the outskirts of Dresden, the state capital of Saxony.
- volytica diagnostics — Our software enables customers to develop more economical battery systems, reduce operational risks and establish second-use concepts.
Wellington Partners is a venture capital firm that invests in technology and life sciences companies, focusing on Digital Media, Software, Electronics & Photonics, Resource Efficiency, and Biotech/Life Sciences. It is committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically leadfinancing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, its own commitment can go as high as € 15 million.Wellington was established in 1998 and has offices in Munich, London, and Zurich.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Series A, Series B, Funding Round
- Germany, United States, United Kingdom
Portfolio highlights
- Nosto — Smarter commerce experience management with AI-fueled personalization, merchandising, and site search
- Minervax — MinervaX is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein : click to read more
- Seamless Therapeutics — Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach to restore health in patients with severe conditions in a safe and precise manner. Seamless technology platform unlocks the reprogramming of recombinases, a highly versatile class of enzymes.
The IFB Innovationsstarter is an innovation funding and investment company of the City of Hamburg providing grants and investments.
Show more
Investment focus
- Software, SaaS, Artificial Intelligence
- Seed, Funding Round, Grant
- Germany, United States
Portfolio highlights
- 3D Spark — Profitability and Sustainability Aligned using 3D Spark's Platform - Empowering Manufacturing with Insights and Efficiency!
- Stargazr — Stargazr is a AI-powered software that enables you to understand your financial data
- Neuralfinity — Neuralfinity provides computer AI services. They generalise machine learning models by utilising an ML API as a service.
BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- Switzerland, Germany, France
Portfolio highlights
- Tricares — TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation.
- ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
- Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
eCAPITAL is a venture capital investor that provides early to growth stage funding to technology and deep tech companies.
Show more
Investment focus
- Information Technology, Software, Manufacturing
- Series A, Funding Round, Series B
- Germany, United States, Italy
Portfolio highlights
- BeeOLED — BeeOLED’s technology enables OLED displays with significantly improved efficiency, brightness and operational stability at lower overall costs due to a less complex device structure.
- Build38 — Build38 is a global provider of mobile application protection solutions. Its solution represents a new generation of app-hardening technologies and service that protects apps from known and unknown attacks and opens the market to new digital business models. Build38 protects applications across various industries including automotive, financial,public transport and health care. Build38 is headquartered in Munich with global offices in Barcelona and Singapore. The company is a spin out of Giesecke + Devrient and ranks among the best IT Security startups in Germany. Build38 is an official GARTNER In-App Shielding Market Guide Vendor since 2019 and the first to combine: In-App Shielding + In-App Monitoring + AI-based In-App Reaction.
- QuoIntelligence — Our finished intelligence will significantly reduce your operational risks and allow you to make informed security decisions.
Coparion provides venture capital to accelerate momentum and growth. With a currently active fund of EUR 275 million, Coparion has the means to do so.Coparion supports entrepreneurial vision with know-how, but without intervening in daily business operations. Thanks to in-depth experience in venture capital and in building companies, the Coparionteam discerns potential and opens up new perspectives. Coparion has the substance, tenacity, and creativity required to mutually manage difficult situations successfully.Coparion only invests with co-investors. The fund invests up to EUR 15M per company, usually in several financing rounds of EUR 0.5-8M each. The investment focus is on German companies in the start-up and early growth phases. Coparion is based in Cologne and Berlin.
Show more
Investment focus
- Software, SaaS, FinTech
- Series A, Seed, Series B
- Germany, Switzerland, United States
Portfolio highlights
- Finoa — Finoa is the leading European crypto-asset management platform, empowering businesses and institutions to engage with crypto safely and intuitively.
- Protembis — ProtEmbo is designed to be a simple and reliable solution for one of the most feared complications during TAVR.The advent of transcatheter treatments for valvular heart disease has been a major revolution in the care of patients with disabilities or intercurrent illnesses that precluded undergoing stressful open cardiac surgical procedures.Nonetheless, in spite of ongoing improvements in TAVR procedures and outcomes, the occurrence of cerebrovascular events represents a significant morbidity of TAVR.Protembis was founded based on the vision to reduce the risk of cerebrovascular events, thereby improving outcomes and making TAVR even safer – especially in light of TAVR shifting to younger and lower-risk patients. The ProtEmbo System is an adjunctive device used during TAVR and removed following completion of valve implantation. The ProtEmbo is an intra-aortic filter device that is designed to deflect embolic material arising during TAVR away from the cerebral circulation.
- Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
Innovative post-revenue startups with first customers trust us as highly reliable investors. We have been an active player in the venture capital market for over 25 years. Due to our evergreen approach, we offer institutional venture capital without the limitations of the usual fund structure. Predominantly we invest straight equity. Additionally,we can offer venture debt to mature startups close to break-even in order to avoid further dilution for founders. Being a private investment company we act as both lead investor or co-investor. We can also fulfill the private lead investor role for public investors like Bayern Kapital. Together we are increasing YOUR company's value.
Show more
Investment focus
- Software, Information Technology, Health Care
- Funding Round, Series A, Series B
- Germany, Italy, United States
Portfolio highlights
- memtime — memtime shows you everything you worked on during the day. Each program is recorded so that you can quickly remember. Add-on available for any software. | memtime
- SUSHI Bikes — SUSHI Bikes has developed the perfect e-bike for modern urban people.
- Kloster Kitchen — Kloster Kitchen is a monastery kitchen as the root of unique taste.
Impacting the future of medicine.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Series C
- United States, United Kingdom, The Netherlands
Portfolio highlights
- Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
- Calluna Pharma — Join Calluna Pharma on our mission to revolutionize the treatment of inflammatory and fibrotic diseases. With a robust pipeline, seasoned leadership, and strategic alliances, help us reshape the treatment landscape for the better.
- Orbis Medicines — Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.
bmp Ventures is an innovative Venture Capital Company from Berlin.
Since 1997 we’ve been investing Smart Money in Early Stage and Growth Startups. We finance ingenious business models with outstanding teams, who build fast-growing and sustainably profitable enterprises.
Show more
Investment focus
- Information Technology, Software, Manufacturing
- Seed, Funding Round, Series A
- Germany, United States, Austria
Portfolio highlights
- Neotiv — Enabling cognitive health
- RAYDIAX — We are Raydiax.Interventional only.Our goal is to reinvent computer tomography that is focussed on treatment.
- InLine-Med — Radiologists perform safe, precise & easy interventions with the InLine-Med surgical tools and assistance devices.
Techno Venture Management is a venture capital and private equity firm focused on healthcare industry.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Series C
- United States, Germany, United Kingdom
Portfolio highlights
- Streaming21 — Checkout the full domain details of Streaming21.com. Click Buy Now to instantly start the transaction or Make an offer to the seller!
- Revolt Technology — News & Informations
- Helomics — Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizing a proprietary set of laboratory platforms that leverage both tissue-based live and fixed cellular basedanalysis allowing physicians to characterize malignant tumors on a personalized basis. Helomics’ novel molecular and cellular markers and bioinformatics services support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.
EMBL Ventures invest throughout Europe with the aim to build companies that create significant commercial opportunities based on new therapeutic treatment.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- Germany, Austria, Ireland
Portfolio highlights
- Arsanis — Arsanis is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with access to some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to build andadvance a pipeline of novel mAbs with multiple mechanisms of action and high potency against their intended targets.The company’s lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, its preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).
- Topas Therapeutics — Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. The Topas Particle Conjugates technology platform induces antigen-specific immune tolerance by harnessing the liver’s naturalimmunology capabilities. The Company has several proprietary programs; lead product candidate TPM203 has recently entered clinical testing for pemphigus vulgaris, an orphan disease. Other programs are in anti-drug antibodies, celiac disease, Type 1 diabetes, as well as a multiple sclerosis program that is available for partnering.Topas has a research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction and a multi-year agreement with Boehringer Ingelheim to collaborate in the field of anti-drug antibodies.Topas’ investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund.
- Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
We have been investing at the frontier of technology and science for over 30 years. We know what it takes to succeed.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Series A, Funding Round, Series B
- Germany, Switzerland, United States
Portfolio highlights
- Ledgy — Digitize your cap table, automate equity plans and simplify compliance. Find out how leading companies use Ledgy to empower their employees and engage investors.
- HeyJobs — Intelligent recruiting | more hires with performance marketing | only qualified candidates | fast recruiting success | over 1,500 companies use HeyJobs to find employees
- Humanoo — HUMANOO | MAKING PEOPLE HEALTHIER! HUMANOO is the digital health platform for employees and insurance clients. We enable our users to improve their physical and mental health. Simple, effective, proven - all in one app. With customized programs and innovative eHealth solutions, we guide our users in the areas of fitness, physio, yoga, mindfulnessand nutrition to their self-imposed goals. For the first time, companies and insurance companies can use comprehensive decentralized analysis to understand the health of their employees or insurance clients and make it a measurable success. Our team currently consists of 65 employees from 15 nations with different talents. In our office in Berlin-Kreuzberg, software developers, designers, marketing and sales specialists work together with sports and nutrition scientists as well as yoga teachers and physiotherapists. What we share is the goal to motivate people to stay healthy.
bm|t supports innovative and growth-oriented companies in Thuringia with equity investments and venture capital.
Show more
Investment focus
- Software, Information Technology, Health Care
- Seed, Funding Round, Series A
- Germany, United States
Portfolio highlights
- rooom.com — rooom is a global startup based in Germany, launched in 2019. The company’s experienceCloud is an all-in-one platform for creating, managing and promoting engaging 2D, 3D, AR & VR experiences. It works across all desktop and mobile devices. rooom’s experienceCloud is designed to cover the marketing and visualization needs of differentindustries through their comprehensive product portfolio. These include eventCloud (optimized for virtual events, exhibitions, conferences, meetings), spaceCloud (real estate, property, museums), productCloud (3D products, product showrooms) and immerseCloud (tours, guides, 3D books). rooom’s eventCloud is routinely hosting up to 200,000 users for hybrid events like IFA, Berlin and for global customers such as Porsche, Deutsche Telekom, DHL and E.ON. rooom has won over 20 awards, including the Global Eventex Award (twice), the Innovation & Excellence Award and the German Innovation Award.
- tediro — tediro develops a mobile robotics platform for multiple applications in healthcare primarily therapy and diagnostics
- Coachwhisperer — Coachwhisperer offers smart intercom and monitoring system for coaches and athletes.
Amino Collective is an investment firm. They enable entrepreneurs and scientists to establish businesses that generate a better future for all species on Earth. The firm intends to invest in the sectors of biology, biotech, health tech, science, digital health, life science, and synthetic biology.
Show more
Investment focus
- Health Care, Biotechnology, Software
- Seed, Series A, Pre-Seed
- Germany, United States, United Kingdom
Portfolio highlights
- Biomia — Biomia is a synthetic biology company developing plant-derived natural products for unmet medical needs in pain, addiction, and depression.
- Anima — Anima's online patient triage speeds up the clinical workflow 10x and allows providers to deliver the right care for patients within 24 hours.Millions of patients with serious problems are missed and die every year because there isn’t adequate information flow between medical appointments. Patients submit their problems and requests onAnimainstead of waiting for an appointment, and Anima sends an actionable report to their provider with trends, risks and recommendations.
- Lindus Health — Lindus Health. From recruitment to delivery, we accelerate clinical trials. Our mission is to make health research accessible for everyone, everywhere.
S-Venture Capital Dortmund aims to fund technology companies and is a German regional investment group.
Show more
Investment focus
- Biotechnology, Guides, Genetics
- Series B, Funding Round, Series A
- Germany
Portfolio highlights
- Innolume — Innolume has invented a novel comb laser light engine for short-reach optical interconnects between and within computers. Economical wavelength-division multiplexing (WDM) is enabled by this class of low-cost, low-power Fabry-Perot lasers. WDM, familiar from telecom, provides an efficient alternative to multiple lasers and underutilized parallelfiber/waveguides, reducing short-reach system cost and power.
- Protagen — Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address anumber of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases.The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.
- Scienion — SCIENION AG is a life science company well positioned in the markets of ultra-low volume liquid handling systems and microarray technologies. They provide their customers with an integrated product portfolio facilitating and improving multiparallel bioanalytics, high throughput screening and high throughput production of microarrays in the genomicsand proteomics fields – from early research to manufacturing.
Seed Fonds has a strong competence network with national and international investors, business angels & expertes from the industry. They are specialized in the development of comprehensive financing models offering stability and development opportunities on the long term.
Show more
Investment focus
- Biotechnology, Medical, Health Care
- Funding Round, Seed, Series A
- Germany
Portfolio highlights
- miacosa — miacosa.de is operated by the Endorsed Goods GmbH. miacosa.de is a social shopping concept from Germany based in Cologne. Social Shopping the miacosa way means that members select their personal shopping team of experts and celebrities that present products they love on miacosa.de Miacosa is for members only. The free service starts with productsfrom the fields of Health Style, Home & Living, Kitchen and fashion accessories.
- Hemovent — Based in Aachen, Germany, Hemovent is a privately held medical technology company that is developing a portable ECMO (Extra Corporeal Membrane Oxygenation) unit. Hemovent was founded by serial entrepreneur, Christof Lenz and Oliver Marseille, inventors of the company’s proprietary platform. It is the goal of the company to develop aninnovative solution, with precision and craftsmanship, that will aide patients with lung and heart function while allowing them to be mobile.
- aquila biolabs — aquila biolabs is a German technology company focusing on the development of innovative laboratory devices for the analysis of shake-flask fermentations in biotechnological, chemical and pharmaceutical research and development.
IBB Ventures is a venture capital and mezzanine arm of Investitionsbank Berlin specializing in seed/startup, early venture, and mid venture investments. The firm invests in technology-oriented companies and companies from the creative industries. It typically invests in information and communication sector with a focus on hardware andsoftware, network technology, new media, and internet and mobile technologies; life science sector with a focus on biotechnology and media technology; and industrial technologies sector with a focus on software, PPS, supply chain management, micro and nanotechnology, environmental and power technology, automation, manufacturing technology, transport technology and logistics, and new materials. The firm also invests in movies, broadcast, television, publisher, music, entertainment, advertising, fashion, design, architecture, multimedia, games, software, and art and culture. It invests in companies based in Berlin. It typically invests between €0.25 million ($0.32 million) and €3 million ($3.83 million) per transaction. The firm prefers to take a board seat in its portfolio companies. IBB Ventures was founded in 1997 and is based in Berlin, Germany.
Show more
Investment focus
- Software, Health Care, Internet
- Seed, Funding Round, Series A
- Germany, United States, United Kingdom
Portfolio highlights
- Quantistry — Move beyond traditional chemical simulation software and boost your R&D success. From Quantum to AI. Get started!
- Meloon — Meloon captures and converts carbon dioxide from the atmosphere.
- Elucid Social — Elucid Social integrates businesses with the social good movement through a data-driven strategy that yields measurable results. Elucid Social develops and deploys technologies to assess, report, and minimize human rights risks linked with the sourcing of products and services.
start-ups, SMEs, technology, co-investment
Show more
Investment focus
- Biotechnology, Health Care, Information Technology
- Pre-Seed, Seed, Funding Round
- Germany, The Netherlands, Austria
Portfolio highlights
- Filuta AI — Operationalized Composite Artificial Intelligence
- Resistell AG — Resistell is a antibiotic resistance test.
- iThera Medical — Due to its spatiotemporal resolution, penetration depth, sensitivity and specificity, optoacoustic imaging (OAI) can be used for a multitude of applications.
With a track record of over 20 years in venture capital and experience from more than 200 investments in numerous companies BFB Brandenburg Kapital GmbH (BFB) is the most active equity investor in Brandenburg. BFB invests in fast-growing technology-orientated companies throughout the whole life-cycle. Target sectors are ICT/Digital Economy,Life Science, MedTech, Proptech, Industrial Applications. BFB invests in companies based in or with facilities in Brandenburg. The current VC fund is financed by the European Regional Development Fund (ERDF) an Investitionsbank des Landes Brandenburg (ILB).
Show more
Investment focus
- Software, Health Care, Information Technology
- Seed, Series A, Funding Round
- Germany, United Kingdom
Portfolio highlights
- Seqstant — Seqstant offers the LiveGene platform for real-time pathogen analysis, allowing for sensitive, specific, and user-friendly real-time genetic diagnostics.
- IQONIC.AI — Creating AI Solutions for Skin, Hair & Inner Balance
- Doctorflix — Doctorflix is a medical education platform that allows doctors around the globe to learn about methods of treatment while accelerating their system-required professional development. We are on a mission to build an engine that simplifies and democratizes the consumption and exchange of medical knowledge by interlinking doctors, hospitals, andpharmaceutical companies.
TVM Capital Life Science is one of the transatlantic Venture Capital pioneers with teams based in North America and Europe.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series B, Funding Round, Series C
- United States, Germany, United Kingdom
Portfolio highlights
- Definiens — Definiens is the provider of image analysis and data mining solutions for quantitative digital pathology in the life sciences, diagnostic biomarkers and healthcare industries. Definiens software provides detailed readouts from whole tissue slides, cell-based assays and full body scans and allows correlating this information with data derived fromother sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and supports better decisions in research, diagnostics and therapy. Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients’ lives. Definiens is headquartered in Munich, Germany, and has offices throughout the United States.
- Lamab Biologics — Lamab Biologics operates as a biotechnology company. Lamab Biologics develop first-in-class monoclonal antibody prophylactic therapeutic targeting IgE, a key mediator for allergic diseases.
- Rapid Micro Biosystems — Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to RapidMicro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.
EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, The Netherlands, Switzerland
Portfolio highlights
- Onera Health — Introduction to Onera sleep diagnostics and monitoring solutions
- Vico Therapeutics — Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.
- Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
Grazia Equity is a venture Capital firm investing in innovative, technology driven startups with high potential.Based in Stuttgart (Germany), Grazia has been supporting a large number of mostly young companies, often from their foundation to the Initial Public Offering or eventual sale.
In contrast to other venture capital firms, theypredominantly work with their own capital that they invest as entrepreneurs.
Show more
Investment focus
- Internet, E-Commerce, Biotechnology
- Series A, Seed, Series B
- Germany, United States, Switzerland
Portfolio highlights
- VYTAL — Start the Packaging Revolution! We are offering smart & reusable To-Go Packaging-as-a-Service to gastronomy clients & consumers.In Germany the consumption of take-away, convenience and delivery food & drinks is responsible for about 281 kilotons of single-use packaging waste for immediate consumption and is growing at double digitrates. Most of the time, To-Go food containers, snack boxes or coffee cups have a very short life-span of only 30 minutes after which they are tossed into trash (or litter parks, beaches & the ocean). This is not only a giant waste of economic resources as each single use costs between 15 and up to 0,60€ for a stable bowl/box with a lid. It is a horrendous waste of environmental resources (wood, water, crude oil, metals & energy) that are used to produce this packaging. Therefore, a single use packaging not weighing more than 30 grams can easily come with an ecological backpack of more than 8 kilograms when taking into account all the resources used in production (material intensities taken from Wuppertal Institute for Climate, Environment and Energy). Looking at GHG emissions, the picture is similarly bleak: Using CO2 emission factors and the detailed material mix of the single-use packaging waste analyzed by NABU (German Nature and Biodiversity Conservation Union), the 281 thousand tons waste from To-Go consumption generated around 556 thousand tons of CO2 or the equivalent of 195k passenger cars per year (assuming an average distance travelled of 15,000km). With the expected rise of take-away, convenience and delivery food, the related emissions are expected to increase at double digit rates as waste volume is expected to increase and as we saw a shift to plastics relative to cardboard or other materials. While there is a growing awareness of the problem, especially in Germany, there is no scalable solution yet and the commonly used alternative of nature-based & ‘biodegradable’ materials like bagasse or PLA also require many resources for production & transport, and have to be incinerated or go to landfill after use as there is currently no way to compost them.
- ZAGENO — ZAGENO is a multi-vendor, online marketplace of life science products which, by simplifying the procurement process, saves more time for science.
- Hypatos — Manual document processing is a major cost driver. Hypatos' deep learning tech automates complex document processing tasks. Make back office more efficient!
Think.Health invests as a boutique risk-taker in healthcare ventures. We continuously seek innovations and disruptive business models in digital healthcare, medical technologies and health service providers,
Show more
Investment focus
- Health Care, Biotechnology, Medical Device
- Seed, Series A, Series B
- Germany, United States, Switzerland
Portfolio highlights
- Vara — Vara develops a breast cancer screening platform powered by AI for radiologists, allowing them to focus on finding cancer early. While we provide. Vara also provides remote mammography reading services to those that lack the radiologists. Vara's mission is to make affordable diagnostics available all over the world by designing machinelearning-powered workflows that users love to work with.
- anvajo — Originally started at TU Dresden, anvajo can now look back on several years of innovative research and successful product development with uninterrupted growth. As part of the business expansion and ongoing team building, anvajo moved into its new headquarters in Dresden in January 2020. On 1300 m² practically all areas, including development,production and support functions are united under one roof.
- Navignostics — Our mission is to identify the ideal treatment to battle each cancer patient’s disease and reduce suffering throughout their journey.At Navignostics we characterize tumors using spatial single-cell proteomics. We use our unique capabilities to identify a cancer treatment that will optimally fight each patient’s tumor. We also accelerate cancerdrug development by providing key insights into drug mechanisms and tumor features for companion diagnostic development.Our highly robust and reliable technology and our leading data analytics position us ideally to enable precision cancer diagnostics for patients and to provide services to pharma and biotech partners.This way we help people suffering from cancer by making more drugs available and by finding the right one for every patient.
BlueYard backs founders building the interconnected elements that can become the fabric of our future.
Show more
Investment focus
- Software, Cryptocurrency, Internet
- Seed, Series A, Funding Round
- United States, Germany, France
Portfolio highlights
- Zafrens — Zafrens specializes in developing tools and generating insights at the interface of biology, chemistry, and engineering. The company was founded in 2021 and is headquartered in San Diego, California, United States.
- Ingonyama — Ingonyama is a next-generation semiconductor company, focusing on Zero-Knowledge Proof hardware acceleration. We build accelerators for advanced cryptography, unlocking real-time applications.
- Privy — With a few lines of code, securely integrate sensitive data into your product. Build delightful, privacy-preserving experiences without putting your users at risk.
Investing in the Future of Protein.We invest in visionary founders creating the future of food and materials.
Show more
Investment focus
- Food and Beverage, Food Processing, Biotechnology
- Series A, Seed, Series B
- United States, Israel, United Kingdom
Portfolio highlights
- ENOUGH — ENOUGH makes protein sustainable by producing ABUNDA mycoprotein, made by fermenting fungi with the natural sugars from grains. It is a whole protein with all 9 essential amino acids & rich in fibre. It is a B2B ingredient, neutral in taste and fibrous in texture, like meat. The most sustainable
- PoLoPo — PoLoPo is a biotech company that produces proteins on a large scale and according to specifications. PoLoPo develops a "superAA" plant by employing directed metabolic engineering techniques and fully utilizing plants' capacity as various metabolite and green protein factories. A significant amount of free amino acids can be producedby the superAA. The increased production of amino acids is then translated into an increase in the scale at which proteins are produced in plant organs.
- Wanda Fish Technologies — Wanda Fish is an innovative FoodTech company with a platform that produces a wide variety of delicious fish fillets using sustainable cell-cultivation practices.
German Federal Ministry of Education and Research (BMBF)
Show more
Investment focus
- Biotechnology, Medical, Health Care
- Grant, Seed, Series B
- Germany, United States, Denmark
Portfolio highlights
- eClear — eClear is a Pan-European payment facilitator providing Customs & VAT Clearing as embedded checkout-solution for marketplaces & platforms.
- Evotec — Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capitalists. Drug discovery solutions are provided in form of fee-for-service work, integrated drug discovery alliances,development partnerships, licensing of innovative drug candidates, and consulting arrangements. The company operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, diabetes, and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, and fibrosis. By leveraging this expertise, Evotec intends to develop best-in-class and first-in-class differentiated therapeutics on its systematic, unbiased, and comprehensive infrastructure.Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB, and others. In addition, the company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Sanofi in the field of diabetes and cancer immunotherapy, with Pfizer in the field of tissue fibrosis, with Bayer in the field of kidney diseases, and with Celgene in the field of neurodegenerative diseases.
- NVision Imaging Technologies — NVision Imaging Technologies is leveraging advances in quantum physics to enable the first routine, convenient and affordable use of Magnetic Resonance Imaging (MRI) for assessing early patient response to cancer treatment at the metabolic level.
96
Normal
0
false
false
false
EN-GB
X-NONE
X-NONE
Show more
Investment focus
- Medical, Health Care, Biotechnology
- Series A, Seed, Series B
- Germany, Finland, The Netherlands
Portfolio highlights
- Surgify — Surgify are currently preparing the commercialization of a novel technology for bone surgery at Aalto University with financial support from Tekes (Finnish Funding Agency for Innovation). To enable continuous communication with clinicians, they have been working in close cooperation with Neurosurgical Department of Helsinki University CentralHospital, part of HUS (The Hospital District of Helsinki and Uusimaa).
- ATRO Medical — ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials that started in 2010 with a consortium of universities, private companies, and financial support from the Dutch government. The collaboration between the clinical, biomechanical, and polymer expertise hascreated the base for the Trammpolin design and the development towards a prototype.
- microDimensions — microDimensions provides digital pathology software and services: image analysis, 3D histology reconstruction, protein multiplexing, stereology, image registration.
Collaboration with outstanding initiators with exceptional insights, from inception through all levels of progress. Lima Ventures supports visionary founders as well as provides certain services to early startups. We seek innovative technology-driven entrepreneurs who generate and lead companies that will inspire millions.
Show more
Investment focus
- Artificial Intelligence, Software, Digital Marketing
- Seed, Pre-Seed, Funding Round
- Turkey, United Kingdom, Estonia
Portfolio highlights
- VRLab Academy — VRLab Academy specializes in implementing advanced virtual science education to institutions. It focuses on waste-free, attractive, and useful design to makes advanced virtual science education possible. The company aims to evolve the educational environment where students will improve their scientific skills and learn all about it from firsthand.
- Studio Billion — Studio Billion is a game development company that develops applications, games, and projects for different platforms. Studio Billion is headquartered in Istanbul, Turkey.
- Enqura Information Technologies — Enqura Information Technologies offers advanced technologies in conjunction with human resources as reasonable solutions. Enqura develops creative solutions in the field of digital transformation. They provide innovative and end-to-end solutions to several industries, primarily finance and insurance.
Seventure Partners is a French venture capital firm targeting in information and communication technology, and life sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with€ 660 million under management as of December 31, 2016. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Series A, Funding Round, Series B
- France, United States, Germany
Portfolio highlights
- Sinay — Use the full potential of your data with intelligent solutions. Become more efficient on a daily basis and reduce your environmental impact.
- Allozymes — Allozymes, Pte. Ltd. is a leading deep technology company applying innovative ultrahigh-throughput microfluidics technology to accelerate enzyme evolution and development. We developed sensitive, accurate, and generic assays for the detection of enzymatic reactions, proprietary microfluidic chips and proteomics technologies to take enzymedevelopment to the next level.
- Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
UVC Partners is a Munich- and Berlin-based early-stage venture capital firm that invests in technology-based startups in the areas of enterprise software, industrial technologies, and mobility. The fund typically invests between € 0.5 - 10m initially and up to € 20m in total per company.
Show more
Investment focus
- Software, Information Technology, SaaS
- Seed, Series A, Series B
- Germany, Switzerland, Denmark
Portfolio highlights
- Cyclize — Cyclize enables a carbon circular economy with innovative plasma sources for chemical recycling, CO2-splitting, and gas reforming.
- FINN — At finn our mission is to make mobility fun and sustainable: We help everyone who loves driving their own car but refuses the struggle, commitment and intransparent costs associated with car ownership. We achieve this by offering all-inclusive, immediately available, monthly car-subscriptions. Best thing, yet: While you drive we plant trees asevery journey is CO2 compensated.
- Reel Energy — Accelerate the transition to a society powered 100% by renewables. Reduce your company's carbon footprint with electricity from new solar parks and wind farms.
EQT Ventures is a European VC fund with just over €2.3 billion in total capital raised. EQT Ventures I launched in May 2016, with commitments totalling €566 million and a simple mission - to be the kind of VC the team would have liked to have had on their own startup journeys. Recognizing that building and growing a company takes more than justcapital, the EQT Ventures team provides founders with support and advice throughout different stages of growth. EQT Ventures doesn't focus on particular markets or industries, but bold and ambitious founders who have the grit and determination to build global success stories. EQT Ventures II launched in November 2019, with commitments totalling €660 million. EQT Ventures III launched in 2022, with commitments totalling €1.1 billion, making it the biggest European Venture Capital fund committed to early stage tech startups. The EQT Ventures team is based across six offices in London, Stockholm, Berlin, Paris, Amsterdam, Paris and San Francisco, taking a locals with locals approach and supporting founders on the ground. Motherbrain, EQT Ventures' in-house-developed artificial intelligence (AI) platform, ensures the team has data-driven approach and has driven more than $100 million in portfolio company investments.
Show more
Investment focus
- Software, Information Technology, Artificial Intelligence
- Series A, Series B, Seed
- Sweden, Germany, United States
Portfolio highlights
- Hume AI — The AI toolkit to measure, understand, and improve how technology affects human emotion
- Heart Aerospace — Heart’s mission is to create the fastest, most affordable and sustainable transportation for regional travel to every corner of the world. Their first aircraft is the ES-19, a nineteen-passenger airliner with an operating range of 400 km. Heart's goal is to have the aircraft certified for commercial operation by 2026.
- Generative Engineering — Generative Engineering is a deep-tech startup with a unique platform that generates, tests, and simulates thousands of different engineering designs, all within a fraction of the time these processes take today. This parallel engineering will radically decrease product development time, enabling innovative designs for all real-world products.
Global Asset Fund is a private equity firm based in Germany that finances early and later stage venture investments. The fund enables the development of products and technologies that address a growing market of tomorrow.
Show more
Investment focus
- Medical, Therapeutics, Biotechnology
- Series A, Series B, Funding Round
- Germany
Portfolio highlights
- Siltectra — SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials.
- Isarna Therapeutics — Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.
Andera Partners, formerly known as Edmond de Rothschild Investment Partners (EdRIP) As heir to the traditions and values that have ensured the success of the Rothschild family for 250 years, the Edmond de Rothschild Group has established itself over time as a leading player in European finance. Its activities are grouped around two major areas:Private Banking and Asset Management. The Group offers wealthy families, entrepreneurs, and large institutions a full range of solutions combining a culture of tailored solutions, stability, performance, and innovation.
The Edmond de Rothschild Group’s offering is characterised by strong convictions, with the desire to guarantee to each of its customers: A unique, close relationship, underpinned by the know-how and the variety of expertise of a large international group; Autonomous, experienced teams, who anticipate economic trends and innovate to establish long-term performance; The recognised stability, strength, and independence of a family-owned financial group. Founded by Baron Edmond de Rothschild in 1953, the Group has been chaired by his son, Baron Benjamin de Rothschild, since 1997.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Private Equity, Funding Round
- France, United States, Germany
Portfolio highlights
- MMI — The future of Microsurgery: microinstruments that expand the possibilities of surgical interventions. Wristed robotic microinstruments for unprecedented results in microsurgery.
- ENYO Pharma — ENYO Pharma is a biopharmaceutical company incorporated in Jan, 2014, by four scientists of the Infectiology Research Center in Lyon, France, and three seeding partners (2 privates and 1 public).The company is based in the Infectiology Center of Lyonbiopôle in Lyon, France and maintains tight collaborations with the seminal Inserm team and theBSL4 laboratory Inserm-Jean Mérieux.ENYO Pharma has licensed several Inserm patents issued from the discoveries of the founding scientists and developed a unique platform for the identification of intracellular therapeutic targets and molecules.The company is developing treatments against the most important viruses and is thriving to become a global leader in anti-virals. Research and Development is currently focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company plans to conduct its molecules to Phase II clinical trials.
- Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
Delivery Hero Ventures is backed by Delivery Hero, a truly global food delivery platform - whose network, distribution and expertise can be harnessed to help our portfolio companies fulfill their global ambitions.
Show more
Investment focus
- E-Commerce, Information Technology, Food Delivery
- Series A, Seed, Series B
- Singapore, Egypt, Brazil
Portfolio highlights
- Qashier — One Qashier solution streamlines POS & payment operations empowering businesses to thrive in the digital economy. Be More with Qashier.
- Flash Coffee — Flash Coffee is a tech-enabled coffee chain that customers use their app to order and pay online, choosing to pick up orders from one of the Flash Coffee’s storefronts or order for delivery through major platforms in each market. Flash Coffee was founded in 2019 and is headquartered in Singapore.
- Bluu Seafood — Cultivated Seafood Made From Fish Cells. Tastier, Healther and More Sustainable.
LSP BioVentures is a venture capital fund focused on opportunities in the life science arena. Based in Cambridge (MA) in the USA; the fund’s management combines the strength of its parent company, Life Sciences Partners Venture Capital firm in Europe and a dedicated team of experts in the USA.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, Germany, United Kingdom
Portfolio highlights
- Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
- Muna Therapeutics — Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's.
- HotSpot Therapeutics — HotSpot Therapeutics is a biotech startup that focuses on the development of allosteric therapies targeting regulatory sites on proteins. It develops a therapy platform to discover medicines and provide proper treatment to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspotstructures, harnessing the power of data science in its multidisciplinary approach to drug discovery, and helps patients to get treatment against several diseases.HotSpot Therapeutics was founded in 2017 and is headquartered in Boston, Massachusetts.
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series C, Series B, Series A
- United States, The Netherlands, Germany
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Argá Medtech — Developing the next generation of Pulsed Field Ablation and Irreversible Electroporation Venture-capital backed company
- GT Medical Technologies — At GT Medical Technologies, our purpose is Improving the Lives of Patients with Brain Tumors. GammaTile Therapy is Surgically Targeted Radiation Therapy (STaRT) for patients with brain tumors.
Occident is an international, privately held investment company based in Zug and Munich. Our goal is to manage our own wealth in a sustainable, meaningful manner seeking to make a positive contribution to society through our investments.
Venture Capital is the focus of our investment activities. We see ourselves as a long-term oriented enabler forinnovative start-ups and visionary founders. As a complementary team of experts, we are fascinated by technologically sound topics (deep tech) from the life sciences, digital and high-tech sectors with the potential to decisively improve people's lives.
Show more
Investment focus
- Health Care, Medical Device, Biotechnology
- Series A, Series C, Funding Round
- Germany, Switzerland, Slovenia
Portfolio highlights
- ReCatalyst — REvolutionizing the way we make fuel cell CATALYSTs
- Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
- Lunaphore — Lunaphore Technologies is a spatial biology company, building multiplex immunofluorescence & IHC solutions for discovery and immuno-oncology research
The EnjoyVenture Management is a private equity company that focuses its investments on the seed and early-stage companies.
Show more
Investment focus
- Software, E-Commerce, Information Technology
- Seed, Series A, Funding Round
- Germany, Portugal, United States
Portfolio highlights
- coapp — coapp brings people and resources together under your brand and handles social and financial transactions between them. Easy!
- MARCLEY — MARCLEY provides a system that enables multi-family building apartment owners to utilize solar energy on their roofs without any financial commitment or additional effort. The generated green power is sold at a cheaper cost than the local basic utility.
- Careloop — Berlin-based HR-tech and EduTech startup with a focus on the German healthcare industry.
S-Refit is a German venture capital firm that invests in biotechnology, mechanical engineering, and software companies.
Show more
Investment focus
- Health Care, Biotechnology, Science/Engineering
- Private Equity
SFO is an entrepreneur from the start-up environment and medium-sized companies. SFO offers complementary expertise, reliable capital, and an effective network.
Show more
Investment focus
- Real Estate, Biotechnology, Manufacturing
- Seed
- Germany
Portfolio highlights
- ecoLocked — ecoLocked is your partner to create a climate-positive built environment. We develop CO2-optimized recipes for concrete based on carbon-negative biochar admixes. Our admixes allow to store captured CO2 in buildings, reduce direct emissions from concrete production, and provide multiple functional benefits, such as improved thermal insulation.
Cipio Partners is a leading European secondary direct and growth capital investment management and advisory firm. The firm makes direct investments in private growth stage technology businesses predominantly in Europe.Founded in 2003, Cipio Partners manages an international portfolio of private growth stage technology businesses in Europe fromoffices in Luxembourg and Munich.
Show more
Investment focus
- Software, Hardware, Internet
- Funding Round, Series B, Series C
- United States, Germany, France
Portfolio highlights
- Wire — Wire is the most secure collaboration platform, transforming the way businesses communicate at the same speed and with the same impact that our founders disrupted telephony with Skype. Headquartered in Berlin with offices in Switzerland and San Francisco, Wire’s award-winning collaboration and communications platform counts over 1,800 governmentand enterprise customers worldwide, including EY, Fortum, the German government and four other G7 governments. Recognized for its secure collaboration platform as a leader and high performer by G2 Crowd, IDC, Forrester and Gartner, Wire offers messaging, audio/video conferencing, file-sharing, and external collaboration - all protected by the most advanced end-to-end encryption.
- NavVis — NavVis next-generation technology for the built environment enables accurate mobile mapping of indoor spaces and enterprise-ready digital twin solutions.
- Nuki Home Solutions — Nuki Home Solutions is the leading supplier of smart home solutions in Europe. The company aims to make access controls smarter and physical keys irrelevant. We believe in the power of mobile technology innovations and use it to facilitate our daily lives.The company is headquartered in Graz, Austria. Nuki Home Solutions operates in the DACHregion, France, UK, BENELUX, Spain and Italy and is working with partners to ensure availability in other European markets.The company’s first product Nuki turns a smartphone into a smart key in only a few minutes. The Smart Lock is mounted on the inside of the existing door lock and is Europe’s first Bluetooth Smart Lock with permanent Internet access. The smart door lock delivers maximum convenience to its customers. By using Bluetooth, Nuki opens the entrance door automatically as soon as an authorized person approaches and closes the door at the push of a button, when you leave the building.
ERP Startfonds KfW finances and supports, among other things, business start-ups, small and medium-sized enterprises.
Show more
Investment focus
- Professional Services
- Series B
- Germany
Portfolio highlights
- tolingo — tolingo is one of the most renowned and successful translation agencies in Germany – a fact which motivates us in our work across every division of our company every day and helps drive us to constantly improve the services we offer to our clients. A human touch is crucial, whether in terms of our employees’ respectful, open interaction with oneanother at our headquarters in Hamburg, our consultations and service meetings with our clients, or the close, productive working relationships we enjoy with our specialist translators and industry experts all over the world. We strive for collaborative success and partnerships on equal footing without losing sight of the expectations we’ve set for ourselves or the standards and goals we’re determined to meet. This is how we’ve been able to transform from a little translation agency into a globally present provider with a sophisticated portfolio of services – with market-leader status in our sights.
- Rodos BioTarget — Rodos BioTarget (RBT) is a biopharmaceutical company developing a targeted drug delivery platform. RBT’s patented TargoSphere® technology enables carrying a broad range of active agents selectively into the center of the immune response - i.e., directly into antigen-presenting cells.RBT currently applies its TargoSphere® technology successfullyin various models of infectious diseases caused by viruses like HCV/ Hepatitis C and HIV/ AIDS and by bacteria like in Tuberculosis, Legionellosis, and MRSA. Yet, any disorder that goes along with either overshooting or insufficient immunity caused by antigen-presenting cells - like chronic inflammations, cancers, allergies, and autoimmune diseases - may be addressed by RBT’s TargoSphere® technology.
- Intelligent Apps — In 2009 founders Niclaus Mewes and Sven Kuelper launched "mytaxi" - the first taxi app with a direct connection between passenger and driver. mytaxi has grown to the fastest growing taxi-app with more than 7 million downloads and 35.000 connected taxis. mytaxi is available in over 40 German cities as well as Washington, Madrid, Barcelona,Warsaw, Vienna, Graz, Salzburg and Zurich. Investors include T-Venture Holding GmbH (Deutsche Telekom AG), Daimler Mobility Services GmbH (Daimler AG), KfW, e42 GmbH and Lars Hinrichs (Cinco Capital GmbH).mytaxi brings a demand for quality to the taxi service for the first time. Every driver using mytaxi has the ability to become a contractor and build their own client base by consistently providing passengers with good service and earning high customer ratings. Through the given peer-to-peer connection between passenger and driver the whole ordering process becomes very transparent for both. The passenger can not only track the taxi’s arrival in the app but also see which driver is coming. For the driver the cost modell is very attractive as they only pay for a successfully completed trip.The aim of mytaxi is to drive the concept of urban mobility and to further strengthen its position as an international leader in this field. Accordingly to that mytaxi took over the app development services for Daimler Mobility Services GmbH (Daimler AG).
Inflection is a first check venture capital firm exploring new frontiers. We run nodes, govern DAOs and write code. We invest between $500k-$1.5M initially and have a global mandate.
Show more
Investment focus
- Software, Financial, Other
- Seed, Funding Round, Pre-Seed
- United States, Germany, Canada
Portfolio highlights
- GitPOAP — GitPOAP is a decentralized reputation platform that represents off-chain accomplishments and contributions on chain as POAPs.
- Hologram Labs — Immerse as your virtual characters, connect with others, and create unforgettable moments on any video and gaming platform.
- Unstoppable Finance — Your DeFi journey starts here. All things DeFi investing at your fingertips. Curated, vetted, verified. Navigate DeFi with confidence.
BM H Beteiligungs-Managementgesellschaft Hessen mbH operates as an investment arm of Landesbank Hessen-Thüringen Girozentrale.
Show more
Investment focus
- Software, SaaS, Health Care
- Seed, Series A, Pre-Seed
- Germany
Portfolio highlights
- Blaue Helden — Blaue Helden set up a DTC operation producing and selling sustainable cleaning products.
- leonardo. impact — Impact investing is a $2.3 trillion industry. Per definition the investment should be linked to positive outcomes that benefit people & planet. Measuring impact is a complex and expensive process, which has led to institutions using their own unique methodology to suit their needs and budget. This leads to reporting errors at best. At worst, itleaves the industry vulnerable to greenwashing. A standardised and automated approach would result in millions in savings, more accuracy & trust.leonardo's B2B SaaS solution combines effective & trustworthy impact measurement with the challenges of fund management & investor relations. We enable effective primary data collection to provide actionable insights into the actual effects of products & services on people & planet through automatically generated surveys and API connections to IoT devices & third party software. With the tool being used by impact businesses & their capital providers, leonardo provides streamlined data pipelines and consistent communication throughout the entire capital flow. The high quality impact data is compliant with regulatory requirements & acknowledged impact reporting standards. Additionally, we leverage machine learning at several stages. First, recommendation engines help the user to select the right frameworks & standards. Large language models help to extract qualitative information from interviews & reports and to utilise it for impact calculations. Most importantly, ML-powered data validation enables us to assess the impact and strongly increases data quality & reporting credibility, thus mitigating the risk for greenwashing while reducing the need for third-party audits.
- Quantagonia — Advanced quantum algorithms, for your most important business problems, delivering breakthrough performance on today's high-performance computers, with seamless migration for later use on quantum computers.
Investors by industry
Health Care
Biotech
Community
Marketplace
FinTech
Impact
Proptech
Media (entertainment)
EdTech
Consumer
Climate
Energy
Hardware
Gaming
Artificial intelligence
Sustainability
Agriculture (agtech)
Venture Capital
Restaurants
Publishing
Beauty
Oil and Gas
Web3
Video Games
Food and Beverage
Clean Energy
Real Estate
Infrastructure
Big Data
Organic Food
Photography
Fashion
Medical
Email
Wellness
Social Media
Music
Franchise
Celebrity
Android
Internet
Legal
Google
eSports
Construction
Local
Mobile
Enterprise Software
Sports
Social Network
Manufacturing
Digital Media
Facebook
Art
Social Impact
Education
Recruiting
Platforms
Travel
Fitness
Mobile Advertising
B2B
Cannabis
Biotechnology
Hospitality
Automotive
Crowdfunding
Renewable Energy
Wine And Spirits
Medical Device
Social
CleanTech
Payments
Transportation
Mobile Apps
Financial Services
InsurTech
Enterprise
Sporting Goods
Finance
Retail
Film
LGBT
Life Science
Theatre
SaaS
Non Profit
Cryptocurrency
Software
Blockchain
Investors by country
Canada
United Kingdom
Ireland
Germany
South Korea
Australia
United States
India
New Zealand
Oceania
Armenia
China
Europe
Indonesia
LATAM
Middle East
Spain
Asia
Japan
South Africa
Qatar
Vietnam
Saudi Arabia
Singapore
Sri Lanka
Brazil
Africa
Czech Republic
Bahrain
Belize
Bermuda
Costa Rica
Belarus
Bulgaria
Denmark
Algeria
Georgia
Gibraltar
Cameroon
Chile
Finland
Estonia
Kuwait
Faroe Islands
Greece
Israel
Jersey
Kazakhstan
Nicaragua
Philippines
Ethiopia
Italy
Mali
Lithuania
Cambodia
Liechtenstein
Kenya
Liberia
Lebanon
Ghana
Mauritius
Morocco
Malaysia
Norway
Peru
Myanmar
Cayman Islands
Panama
Malta
Mexico
Seychelles
Slovenia
Russian Federation
Rwanda
Serbia
Uzbekistan
Togo
Taiwan
Ukraine
Sierra Leone
Turkey
Tunisia
Thailand
Tajikistan
Poland
Uganda
Zimbabwe
Tanzania
San Marino
Uruguay
Venezuela
Zambia
Senegal
Puerto Rico
Portugal
Sweden
El Salvador
Nigeria
Bahamas
Azerbaijan
Iraq
Iceland
Namibia
United Arab Emirates
Hungary
Honduras
Croatia
Isle of Man
Bolivia
Luxembourg
Egypt
Pakistan
Albania
Belgium
Barbados
Ecuador
France
Hong Kong
Austria
Argentina
Bangladesh
Grenada
Jordan
Romania
Cyprus
Latvia
Oman
Switzerland
Colombia
Guatemala
Marshall Islands
VC Funds in Germany by industry
Enterprise
FinTech
Consumer
Biotech
Health Care
Climate
Sustainability
Marketplace
SaaS
Artificial intelligence
Community
Hardware
Agriculture (agtech)
Media (entertainment)
Energy
Crowdfunding
Venture Capital
Restaurants
Real Estate
Fashion
Financial Services
Mobile Apps
Cryptocurrency
Finance
Education
Payments
Food and Beverage
Wine And Spirits
Video Games
Organic Food
Email
Medical
Medical Device
Social Network
Wellness
Social Media
Music
Manufacturing
Art
Digital Media
Blockchain
Mobile
Android
Construction
Local
Legal
Enterprise Software
Sports
eSports
Fitness
Travel
Hospitality
CleanTech
InsurTech
Automotive
Recruiting
Mobile Advertising
Platforms
Cannabis
Biotechnology
Retail
Infrastructure
Social
Beauty
Web3
B2B
Life Science
Sporting Goods
Big Data
Photography
Publishing
Renewable Energy
Clean Energy
EdTech
Internet
Oil and Gas
Impact
Social Impact
Transportation
Software
Proptech
Gaming